A study found some mutations that are already targeted by approved or investigational drugs for prostate cancer, along with dozens of targets that should be considered as candidates for future trials.
In a pivotal trial, combination of nivolumab and ipilimumab yielded improvement in OS and ORR of poor-risk RCC patients.
Combining mitoxantrone and prednisone with adjuvant androgen deprivation therapy failed to improve overall survival over ADT alone in patients with high-risk prostate cancer.
Antibiotics administered within 30 days of starting immunotherapy reduced both PFS and OS for patients with advanced RCC and NSCLC.
Dr. Elizabeth Plimack discusses her 2018 AACR meeting presentation on recent advances in systemic therapy for bladder cancer.
Pembrolizumab offered stable or improved measures of global health status and quality of life compared with chemotherapy in patients with previously treated advanced urothelial cancer.
First-line combination therapy with the PD-L1 inhibitor avelumab and the VEGFR TKI axitinib yielded antitumor activity in previously untreated RCC.
The FDA has granted a Breakthrough Therapy designation to the antibody-drug conjugate enfortumab vedotin for patients with locally advanced or metastatic urothelial cancer.
Increases in resource use were not associated with improved survival or quality of care for patients with metastatic prostate cancer, but were associated with higher healthcare costs.
Proton radiation therapy offers some reduced toxicity over IMRT in patients under the age of 65 with prostate cancer, but its cost is nearly double.